Real-world Assessment of Biosimilar Bevacizumab Uptake for NSCLC, CRC Treatment
An analysis presented at the AMCP 2025 Annual Meeting assessed uptake trends for the bevacizumab biosimilar in patients with non-small cell lung cancer (NSCLC)...
GLP-1 Treatment May Result in Additional Pharmacy Use, Costs
An analysis presented at the AMCP 2025 Annual Meeting found that using glucagon-like peptide-1 receptor agonists (GLP-1s) for treating type 2 diabetes and obesity...
Dextromethorphan-Bupropion Not Cost-effective Compared to First-line Agents for Major Depressive Disorder
Dextromethorphan-bupropion (Auvelity®, Axsome Therapeutics) had improved efficacy for the treatment of major depressive disorder (MDD) compared with standard first-line treatments; however, the therapeutic was...
Did the AMP Cap for Medicaid Rebates Impact Brand-over-generic Strategies?
The American Rescue Plan Act removed the 100% average manufacturer price (AMP) cap for Medicaid rebates, effective Jan. 1, 2024, requiring manufacturers to pay...